Information Provided By: 
Fly News Breaks for October 5, 2015
MGNX
Oct 5, 2015 | 09:15 EDT
Noting that MacroGenics' stock has tumbled nearly 40% over the past three months, Roth Capital says that the decline has significantly discounted the differentiation of the company's cancer treatment, MGA271, and offers an intriguing entry point for long-term investors focused on MacroGenics' DART-platform. Roth keeps a $45 price target and Buy rating on the shares.
News For MGNX From the Last 2 Days
There are no results for your query MGNX
